Approval · Notice of Compliance 4647 · 1996

NAROPIN: Notice of Compliance 4647

Issued December 24, 1996

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 4647
Date: December 24, 1996
Company: Astra Pharma Inc.Mississauga, Ontario, Canada
Product type: Nonprescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: New Active Substance (NAS)
Therapeutic class: Local anesthetic

Products in this notice

Brand	DIN	Status today
NAROPIN	02229411	Marketed
NAROPIN	02229416	Cancelled Post Market
NAROPIN	02229418	Marketed
NAROPIN	02229415	Marketed

Medicinal ingredients

ROPIVACAINE HYDROCHLORIDE 2 MG per ML
ROPIVACAINE HYDROCHLORIDE 7.5 MG per ML
ROPIVACAINE HYDROCHLORIDE 10 MG per ML
ROPIVACAINE HYDROCHLORIDE 5 MG per ML